Increased diabetes and cardiovascular events like CAD, myocardial infarction and sudden cardiac deaths were noted among patients receiving GnRH agonists as ADT compared to patients not receiving any ADT [10]. This evidence concerns the gene GNRH1 and myocardial infarction.